Why the study?
Does a twice-daily aspirin regimen improve platelet inhibition compared to once-daily regimens in patients with essential thrombocythemia?
Does a twice-daily aspirin regimen improve platelet inhibition compared to once-daily regimens in patients with essential thrombocythemia?
In essential thrombocythemia, impaired platelet inhibition by low-dose aspirin is due to accelerated platelet turnover and can be rescued by a twice-daily dosing interval rather than increasing the once-daily dose.
Answers are grounded in this paper and cite their sources.
Twice-daily aspirin may restore efficacy in essential thrombocythemia; confirms accelerated turnover necessitates dosing-interval adjustment over escalation.
Essential thrombocythemia (ET) is characterized by enhanced platelet generation and thrombotic complications. Once-daily low-dose aspirin incompletely inhibits platelet thromboxane A(2) (TXA(2)) in the majority of ET patients. In the present study, we investigated the determinants of aspirin-insensitive platelet TXA(2) biosynthesis and whether it could be further suppressed by changing the aspirin dose, formulation, or dosing interval. In 41 aspirin-treated ET patients, the immature platelet count predicted serum TXB(2) independently of platelet count, age, JAK-2 V617F mutation, or cytoreduction (β = 3.53, P = .001). Twenty-one aspirin-treated patients with serum TXB(2) ≥ 4 ng/mL at 24 hours after dosing were randomized to the following 7-day regimens in a crossover design: enteric-coated aspirin 100 mg twice daily, enteric-coated aspirin 200 mg once daily, or plain aspirin 100 mg once daily. A twice-daily regimen caused a further 88% median (IQR, 78%-92%, P < .001) TXB(2) reduction and normalized the functional platelet response to aspirin, as assessed by urinary 11-dehydro-TXB(2) excretion and the VerifyNow Aspirin assay. Doubling the aspirin dose reduced serum TXB(2) only partially by 39% median (IQR, 29%-54%, P < .05). We conclude that the abnormal megakaryopoiesis characterizing ET accounts for a shorter-lasting antiplatelet effect of low-dose aspirin through faster renewal of platelet cyclooxygenase-1, and impaired platelet inhibition can be rescued by modulating the aspirin dosing interval rather than the dose.
No takes yet. Share an insight, caveat, or question.
Pascale et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: